-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the State Food and Drug Administration showed that Xi’an Janssen’s application for new indications for Darzalex injection (Darzalex) in China (acceptance number: JXSS2000019/20) has been approved by the NMPA.
Xi'an Janssen submitted a listing application for this indication to NMPA in April 2020, and was included in the priority review by CDE in October 2020.
Multiple myeloma (MM) is an incurable hematological malignancy.
CD38 is highly expressed in multiple myeloma cells.
Daratumumab is the first fully human monoclonal antibody targeting CD38 approved globally and domestically.
Medicine Rubik's Cube NextPharma
Medicine Rubik's Cube NextPharmaIn addition, Xi'an Janssen submitted a listing application for Darzalex Faspro in China on November 6 last year.
In addition, the clinical application of Fuhong Henlius daratumumab biosimilar drug was granted the default approval of CDE on January 12 this year.